LEXINGTON, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that company management will present and/or host 1-on-1 meetings at three investor conferences during June 2011 to discuss the company’s business activities, financial outlook, and current news.
- Steven Gilman, EVP and CSO, will present on Monday, June 6, at 8:00 a.m. Eastern Time at the Jefferies 2011 Global Life Sciences Conference at the Grand Hyatt Hotel in New York City. (Live audio with slides webcast.) David McGirr, SVP and CFO, will join Dr. Gilman at this conference.
- Michael Bonney, President and CEO, will participate in a “fireside chat” discussion with an analyst from Goldman Sachs on Tuesday, June 7, at 2:40 p.m. Pacific Time at the 32nd Annual Goldman Sachs Healthcare Conference in Rancho Palos Verdes, California. (Live audio webcast.) Joining Mr. Bonney at this conference will be Eileen McIntyre, Sr. Director, Investor Relations.
- Robert Perez, EVP and COO, will host one-on-one meetings on June 16, at the Leerink Swann Healthcare Access Day in Boston. Mr. Perez will be joined by Ms. McIntyre. These meetings will not be webcast.
The live webcasts of these presentations will be accessible through Cubist’s website at www.cubist.com in the Investor Relations Conference Calendar section. The webcasts will be available for a period of up 30 days after the presentations.
About Cubist
Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. In the U.S., Cubist markets CUBICIN® (daptomycin for injection), the first antibiotic in a class of anti-infectives called lipopeptides, and has an agreement with Optimer Pharmaceuticals, Inc. to co-promote Optimer’s drug, DIFICID™, in the U.S. as a treatment of Clostridium difficile infections. The Cubist clinical product pipeline currently consists of a Phase 2 program focused on the development of a novel cephalosporin to address certain serious infections caused by multi-drug resistant (MDR) Gram-negative organisms and a Phase 2 program for the treatment of CDAD (Clostridium difficile-associated diarrhea). Cubist also is working on several pre-clinical programs being developed to address areas of significant medical needs. These include therapies to treat various serious bacterial infections and agents to treat acute pain. Cubist is headquartered in Lexington, Mass. Additional information can be found at Cubist’s web site at www.cubist.com.
Cubist and CUBICIN are registered trademarks of Cubist Pharmaceuticals, Inc.
DIFICID is a trademark of Optimer Pharmaceuticals, Inc.